Stoke Therapeutics stock price target lowered to $28 at BTIG on Zorevunersen data

Investing.com - BTIG lowered its price target on Stoke Therapeutics (NASDAQ:STOK) to $28 from $29 while maintaining a Buy rating, citing 36-month data for the company’s Zorevunersen (STK-001) treatment. The stock, currently trading near its 52-week high of $18.45, has shown remarkable momentum with a 38% surge in the past week. According to InvestingPro data, the company maintains an EXCELLENT financial health score.

The 36-month data demonstrated deepening seizure reductions in the third year of treatment, even for patients who started at sub-optimal loading doses. Patients who began with the planned 45 mg loading doses showed impressive and sustained results.

The data, comprising approximately 75 patients, appears sufficient to support approval, according to BTIG. The seizure reductions occurred in patients already taking standard of care medications, with the majority either using or having failed Fintepla.

BTIG noted improvement in non-seizure effects that build over time, contrasting with Fintepla, where only about one in eight patients show benefits for symptoms beyond seizures despite its powerful anti-seizure properties.

The firm observed that Stoke’s tone has evolved from conservative to more aggressive regarding accelerated approval possibilities, with the company planning to discuss upcoming 36-week open-label extension data with regulatory agencies.

In other recent news, Stoke Therapeutics Inc reported its Q2 2025 earnings, surpassing analyst expectations. The company posted an earnings per share (EPS) of -$0.40, which was better than the anticipated -$0.50. Revenue for the quarter reached $13.8 million, exceeding the forecasted $9.39 million. These financial results highlight a stronger-than-expected performance for Stoke Therapeutics in the second quarter. The company’s ability to outperform expectations is a significant development for investors. While analyst upgrades or downgrades were not mentioned, the earnings results provide a positive outlook. These recent developments offer insight into the company’s current financial health.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.